钇90微球选择性内放射治疗在肝细胞癌治疗中的研究进展

打开文本图片集

【中图分类号】R735.7

【文献标志码】A【收稿日期】2025-04-23

【AbstractPrimarylivercanerisoneofthe mostcommoncausesofcancer-related deathsin China，with hepatocelularcarcinoma （HCC）accounting for 75% -85%.Approximately 70% of HCC patients are in the advanced stage at the time of diagnosis and miss the opportunity forradicalsurgery，leading toapor prognosis.Ytrium-90microsphereselective internalradiationtherapy（ soY -SIRT）， anemergngtherapeuticmodality，deliversradioactivemicrospheresviathehepaticaterytotargetumorsandusesbetaradiationfor localized tumor ablation. Compared to conventional transarterial chemoembolization and pharmacotherapy，， soY -SIRT shows the advantagesofsignificantclinicalbnefits，goodsafetyprofiles，andbroadapplicabilityacrossdiversepatientpopulatios.Tisrticlee views the advances in the application of 90Y -SIRT in HCC treatment.

【Key wordslytrium-90 microsphere;hepatocellular carcinoma;selective internal radiation therapy

原发性肝癌主要包括肝细胞癌（hepatocellularcarci-noma，HCC）肝内胆管癌以及混合型肝细胞癌-胆管癌3种病理类型，其中HCC占原发性肝癌的 75%～85%[1] 。（剩余21876字）